This inventor holds 1 USPTO granted patent. Top assignee: Step Pharma S.a.s.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Andrew Novak: Innovator in Pharmaceutical Chemistry
Introduction
Andrew Novak is a notable inventor in the field of pharmaceutical chemistry. He has made significant contributions to the development of compounds that target critical pathways in disease treatment. His work focuses on innovative solutions for proliferative diseases, showcasing his expertise and dedication to advancing medical science.
Latest Patents
Andrew Novak holds a patent for N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases. This patent represents a significant advancement in therapeutic options for patients suffering from these conditions.
Career Highlights
Andrew is currently associated with Step Pharma S.a.s., where he continues to innovate and develop new pharmaceutical solutions. His work at Step Pharma has positioned him as a key player in the industry, contributing to the company's mission of improving patient outcomes through advanced therapies.
Collaborations
Andrew has collaborated with talented professionals in his field, including Abdul Quddus and David Cousin. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Andrew Novak's contributions to pharmaceutical chemistry and his innovative patent demonstrate his commitment to improving healthcare solutions. His work continues to inspire advancements in the treatment of proliferative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile